This week on Health Matters, Canada is leading the way with an exciting new treatment to prevent severe COVID-19. Dr. Jean Bourbeau discusses an innovative clinical trial that could change the course of the pandemic for countries around the world.
(Time on Podcast: 0:55) Dr. Jean Bourbeau is leading a phase III clinical trial for a know drug that has been repurposed as a potential treatment for COVID-19. Patients that are either not vaccinated (such as in developing countries with low vaccine access) or those that are immunocompromised, still need access to medications that can reduce the severe effects of COVID-19. The trial involves the use of PULM-001, an oral antibiotic that is well known to physicians, is safe and very affordable, for the treatment of COVID-19. This drug is so promising as a treatment because it is already know to fight infection. Listen to the podcast to learn more about the clinical trial using this repurposed drug.
Listen to the Podcast
The global impact of the MUHC & philanthropy. The MUHC Foundation’s Health Matters. July 11, 2021.